Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03865212 · ClinicalTrials.gov registry record · Phase 1
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03865212: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT03865212 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03865212, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of a modified virus called VSV-IFNbetaTYRP1 in treating patients with stage III-IV melanoma. The vesicular stomatitis virus (VSV) has been altered to include two extra genes: human interferon beta (hIFNbeta), which may protect normal healthy cells from becoming infected with the virus, and TYRP1, which is expressed mainly in melanocytes (specialized skin cell that produces the protective skin-darkening pigment melanin) and melanoma tumor cells, and may trigger a strong immune response to kill the melanoma tumor cells.
Interventions
- DRUG Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-06-12 |
| Est. Completion | 2025-10-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03865212
The ClinicalTrials.gov registry entry for NCT03865212 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1 is the first listed.
NCT03865212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03865212 about?
NCT03865212 is a clinical study titled "Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma". This phase I trial studies the side effects and best dose of a modified virus called VSV-IFNbetaTYRP1 in treating patients with stage III-IV melanoma. The vesicular stomatitis virus (VSV) has been altered to include two extra genes: human interferon beta (hIFNbeta), which may protect normal healthy ...
What is the current status of trial NCT03865212?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-06-12. Estimated completion is 2025-10-12.
What interventions are being tested in trial NCT03865212?
The interventions under investigation include: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1 (DRUG).
Who is sponsoring clinical trial NCT03865212?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.